BREAKING NEWS: Advaxis Reports Preliminary Safety and Survival Data from a Phase 2 Trial in Recurrent/Refractory Cervical Cancer
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies.
Month: January 2012
S.E.A. Medical Secures $3 Million in Series B Financing from JK&B Capital
Healthtech company makes strides towards developing medical devices designed to catch life-threatening IV drug errors before they harm patients
Provectus Receives Guidance From FDA On Pathway to Approval for Phase 3 Trial of PV-10 For Metastatic Melanoma
Dr. Craig Dees talks candidly in a live audio interview about the company’s developments.
This Week In Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
Miracor Aims to Cure More Than 350K Broken Hearts Per Year with New PCI Intervention System
Three million patients are treated for restricted coronary blood flow every year.
Biocept, Inc. Making Advances in Circulating Tumor Cell Research for Cancers
To date, most CTC capture and detection technologies have not been able to recognize the cytokeratin negative (CK‐) CTCs. Biocept’s Cell Enrichment and Extraction (CEETM) platform allows for the capture of these CK- cells as well as CK+ CTC phenotypes
Microvisk Limited Uses Same Technology as iPhone, Wii to Measure Blood Coagulation
The MEMS technology, which was originally developed as a movement system for nano-robots is also used in devices such as the iPhone and Nintendo Wii.
Cervilenz Inc. Reduces Premature Birth Risk with Simple Test
“I am very pleased with the performance of this new device to identify high risk patients so they can be treated appropriately with progesterone therapy to prevent preterm delivery.”
2B BlackBio is Focused on Reducing Mortality Rates with Early Sepsis Detection Kit
A recent product of note is the BlackLight® Sepsis Kit, which is currently under clinical evaluation. The sepsis detection kit has been extensively tested on real hospital samples, which have led to recognition of both common and rarer pathogens.
Editor’s Note February 21, 2012
In this week’s Sentinel: Peter Winter continues to bring us financings and developments in the global diagnostics business. BIO CEO & Investor Conference 2012, held […]